Speech-Language Pathologists in Chester, TX Accepting Medicare
1 Speech-Language Pathologists found. Showing 1 - 1
 Sandra Gilzow Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 273 Yellow Jacket Dr, Chester, TX 75936 Phone: 936-969-2211 |
News Archive
Over 96% of SIDS cases due to known risk factors
Sudden Infant Death Syndrome (SIDS) continues to be the third leading cause of infant death, according to the Centers for Disease Control (CDC), despite a decline in SIDS that is associated with a rise in safe-sleep practices for newborns and infants. A new study by Barbara M. Ostfeld, PhD and Thomas Hegyi, MD, professors in the Department of Pediatrics at UMDNJ-Robert Wood Johnson Medical School, has identified that more than 96 percent of infants who died of SIDS were exposed to known risk factors, among them sleeping on their side or stomach, or exposure to tobacco smoke, and that 78 percent of SIDS cases contained multiple risk factors.
PHI model helps identify top health risks associated with chronic diseases
Public health agencies across the globe are challenged with preventing the spread of chronic diseases while dealing with limited funds and devastating budget cuts.
Positive results from new analyses of denosumab Phase 3 trials
Amgen today announced positive results from several new analyses of two Phase 3 trials studying denosumab compared with Zometa® (zoledronic acid), the current standard of care, for the treatment of bone metastases in patients with advanced breast cancer ("136 study") and solid tumors or multiple myeloma ("244 study"). Results from these trials reinforce denosumab's consistent ability to delay the complications of bone metastases in patients with advanced cancer. These results are being presented during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago.
MD Anderson and Mirati Therapeutics collaborate to expand evaluation of potent KRAS inhibitors
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecules, potent and selective KRAS inhibitors - adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents - which target two of the most frequent KRAS mutations in cancer.
Families of Haitian cholera victims react to U.N. decision to deny compensation for deaths
"The United Nations has come under heavy political fire for its decision to deny compensation for thousands of victims of cholera in Haiti - a deadly disease spread by U.N. peacekeepers in the troubled Caribbean nation," Inter Press Service reports.
› Verified 5 days ago